MedTrace Logo

Early Detection of Familial Hypercholesterolemia in Children

NCT04370899 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2025-04-18

No results posted yet for this study

Summary

Heterozigous FH is an underdiagnosed disease in the paediatric population. Its early detection, would allow us to initiate lifestyle therapeutical changes and early pharmacological therapy if necessary. This is a key fact to reduce atherosclerosis progression and cardiovascular risk in adulthood. Moreover, it will allow, detecting the first and second degree affected relatives.

Conditions

  • Familial Hypercholesterolemia
  • Familial Hypercholesterolemia - Heterozygous
  • Familial Hypercholesterolemia - Homozygous

Interventions

OTHER

lifestyle assessment

A semi-quantitative assessment of the consumption of different food groups will be carried out using a frequency questionnaire validated by the Spanish population27. This questionnaire consists of 137 food items and will be obtained by the dietitian of our Unit (see annex). The child population and/or their parents will be instructed on how to fill the data in the food diary for a period of 3 days, in order to be able to analyse the nutritional composition of the intake and the effect on the lipid profile. The first food register, will be obtained at the collection visit before starting any type of treatment. Another food diary will be included after one year. Physical activity will be collected from the Minnesota Test and we will ask about the consumption of tobacco.

Sponsors & Collaborators

  • Institut Investigacio Sanitaria Pere Virgili

    lead OTHER

Principal Investigators

  • Luis Masana, MD, PhD · Institut Investigacio Sanitaria Pere Virgili

Eligibility

Min Age
2 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-14
Primary Completion
2030-03-14
Completion
2030-07-01

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04370899 on ClinicalTrials.gov